Rofecoxib (Vioxx): a year in review.
Stienburg
K L
KL
D016907:Adverse Drug Reaction Reporting Systems; D002170:Canada; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D012307:Risk Factors; D013450:Sulfones
D004791:Enzyme Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib